Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

A Phase 2 Study to Evaluate the Anti-Tumor Activity of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies

This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as flotetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Study Overview

• Status: Withdrawn
• Conditions: Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Acute Leukemia; Recurrent Acute Lymphoblastic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Lymphoblastic Leukemia; Systemic Mastocytosis; Recurrent Hematologic Malignancy; Hairy Cell Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Biphenotypic Leukemia; Interleukin-3 Receptor Subunit Alpha Positive; Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm; Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm; Refractory Hematologic Malignancy
• Intervention / Treatment: Biological: Anti-CD123/CD3 Monoclonal Antibody MGD006

Detailed Description

PRIMARY OBJECTIVES:

I. Evaluate the anti-tumor activity of flotetuzumab in CD123-positive advanced acute lymphoblastic leukemia (ALL) (Cohort A) and other hematological malignancies (Cohort B), as assessed by complete remission (complete remission [CR]/complete remission with incomplete count recovery [CRi]/complete remission with partial hematological recovery [CRh]) rate.

SECONDARY OBJECTIVES:

I. Evaluate toxicity profile of flotetuzumab. II. Evaluate remission duration among responders. III. Estimate 1-year overall survival. IV. Evaluate minimal residual disease (MRD) status in responders in the ALL cohort.

V. Evaluate the percentage of patients who receive subsequent allogeneic transplantation.

EXPLORATORY OBJECTIVES:

I. Examine immune profile pre- and post-treatment with flotetuzumab. II. Assess the association between CD123 expression and tumor response. III. Assess the association between alterations in tumor genetic or microenvironment with response.

IV. Assess cytokine levels during therapy.

OUTLINE:

Patients receive flotetuzumab intravenously (IV) continuously for 28 days. Patients who achieve partial response or stable disease or any clinical benefit (partial remission [PR], stable disease [SD]) that did not meet CR, CRi, CRh or morphologic leukemia free state (MLFS) criteria receive a second 28-day continuous flotetuzumab IV infusion. Patients who achieve CR/CRi/CRh/MLFS after course 1 or course 2 receive flotetuzumab IV at a 4 days on-3 days off schedule. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then up to 1 year.

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Documented informed consent of the participant and/or legally authorized representative.

  • Assent, when appropriate, will be obtained per institutional guidelines

• Agreement to allow the use of archival tissue from diagnostic tumor biopsies

  • If unavailable, exceptions may be granted with study principal investigator (PI) approval.
• Eastern Cooperative Oncology Group (ECOG) =< 2

• Histologically confirmed diagnosis of

  • Cohort A. Acute lymphoblastic leukemia

    • B-cell phenotype: patients with relapsed or refractory ALL who have received at least 2 prior regimens and failed or are ineligible for CD19-based target therapy
    • T-cell phenotype: patients with relapsed or refractory who have received at least 1 prior regimen

  • Cohort B. Other CD123+ hematological malignancies that failed standard regimens, excluding acute myeloid leukemia and myelodysplastic syndrome

    • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) patients who have failed or relapsed after initial therapy
    • Chronic myeloid leukemia (CML) patients who have failed or relapsed or ineligible for third generation tyrosine kinase inhibitor (ponatinib)
    • Hairy cell leukemia patients who have failed or progressed shortly after purine analogs or failed 2 cycles of purine analog
    • Systemic mastocytosis patients who have failed or progressed on midostaurin
    • Hodgkin lymphoma patients who have failed or relapsed after PD-1/PD-L1- inhibitors and brentuximab vedotin
    • Advanced acute leukemia patients with ambiguous lineage or biphenotypic leukemia that failed 2 lines of prior regimens
    • Patients with any other advanced CD123+ hematological malignancy who have failed standard therapy per the treating physician's judgement
• Relapsed or refractory disease as defined above
• Tumor cells expressing CD123 either by flow cytometry or immunohistochemistry staining as defined below
• Measurable disease of at least 1.5 cm on computed tomography (CT)/magnetic resonance imaging (MRI) for cases without bone marrow involvement
• Peripheral blast count < 20,000/ul at the time of initiation of infusion on cycle 1 day 1
• Life expectancy of at least 4 weeks
• Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 to prior anti-cancer therapy

• Absolute neutrophil count (ANC) >= 750/ul (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated)

  • NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement

• Platelets >= 50,000/ul (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated)

  • NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
• Lumbar puncture to assess presence of central nervous system (CNS) disease if there are symptoms and signs concerning for CNS involvement (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated)
• Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated)
• Aspartate aminotransferase (AST) =< 2.5 x ULN (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated)
• Alanine aminotransferase (ALT) =< 2.5 x ULN (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated)
• Serum creatinine level =< 1.5 times the ULN or a calculated or measured creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated)

• Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV)*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR]) (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated)

  • If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed

• Meets other institutional and federal requirements for infectious disease titer requirements

  • Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy

• Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be performed within14 days prior to day 1 of protocol therapy unless otherwise stated)

  • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

• Agreement by females and males of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.

  • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

• Autologous or allogeneic hematopoietic cell transplant performed within 100 days prior to study drug administration in day 1 of cycle 1 of protocol therapy. However, patients who received allogeneic hematopoietic cell transplantation (HCT) more than 100 days are allowed if no active graft versus host disease (GVHD) > grade 1 and not actively on systemic immunosuppressive therapy
• Chemotherapy, radiation therapy, biological therapy, within 14 days prior to day 1 of protocol therapy. Maintenance-type ALL chemotherapies, including vincristine and mercaptopurine are allowed up to 7 days before starting therapy. High dose steroids are allowed up to 3 days before starting therapy. Cytoreduction with hydroxyurea is allowed to control leukocytosis until to the day of starting therapy. Hydroxyurea can be given during cycle 1 of flotetuzumab administration to control leukocytosis but need to be discussed with the study PI
• Previous treatment with immunotherapeutic agents (for example chimeric antigen receptor [CAR] T cells, long acting bispecific antibodies, etc) in the 28 days period prior to study drug administration on day 1 cycle 1, with the exception of short-half bispecific antibodies (blinatumomab) where the washout period is only 14 days
• Requirement, at the time of study entry, for concurrent steroid > 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, nasal spray or ophthalmic solution
• Use of immunosuppressant medications (other than steroid as noted above) in the 2 weeks prior to study drug administration (cycle 1 day 1)
• Known central nervous system involvement. Patients with suspected CNS involvement must be evaluated by lumber puncture and be free of CNS disease prior to study entry. Previously treated CNS involvement is allowed provided adequate treatment has been provided and the patient is free of CNS disease
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to flotetuzumab
• Any active untreated autoimmune disorders (with the exception of vitiligo)
• Dementia or altered mental status that would preclude sufficient understanding to provide informed consent
• Second primary malignancy that requires active therapy. Adjuvant hormonal therapy is allowed
• Active uncontrolled infection
• Significant pulmonary compromise
• Unstable angina or clinically significant heart disease
• Major trauma or surgery within 4 weeks before enrollment
• Clinically significant uncontrolled illness
• Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection
• Females only: Pregnant or breastfeeding
• Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (flotetuzumab); Patients receive flotetuzumab IV continuously for 28 days. Patients who achieve partial response or stable disease or any clinical benefit (PR, SD) that did not meet CR, CRi, CRh or MLFS criteria receive a second 28-day continuous flotetuzumab IV infusion. Patients who achieve CR/CRi/CRh/MLFS after course 1 or course 2 receive flotetuzumab IV at a 4 days on-3 days off schedule. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Biological: Anti-CD123/CD3 Monoclonal Antibody MGD006; Given IV; Other Names: CD123 x CD3 DART Bi-Specific Antibody MGD006; CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006; MGD006

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Best response of complete remission (complete remission [CR], complete remission with incomplete count recovery [CRi], complete remission with partial hematological recovery [CRh])	Rates and 95% Clopper Pearson binomial confidence interval (CI) will be calculated for complete remission/response rate (confirmed CR/CRi/CRh).	Within the first 4 courses (112 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events	Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, attribution, time of onset, duration, probable association with the study treatment and reversibility or outcome.	Up to 1 year
Minimal residual disease (MRD) as assessed by multi-color flow cytometry		Up to 1 year
Duration of remission		Up to 1 year
Number who bridge to allogeneic hematopoietic cell transplantation	Some of the patients treated on this trial will go on to receive a hematopoietic stem cell transplant. The electronic data capture system will capture those who go on (bridge) to receive a transplant (yes, no). Total number will be based on those patients coded as 'yes'.	Up to 1 year
Percent who bridge to allogeneic hematopoietic cell transplantation	Some of the patients treated on this trial will go on to receive a hematopoietic stem cell transplant. The electronic data capture system will capture those who go on (bridge) to receive a transplant (yes, no). Total number will be based on those patients coded as 'yes'. Percent who bridge will be calculated as follows: number of patients who bridge to transplant divided by total number of patients treated on this trial.	Up to 1 year
Overall survival	Will be estimated using the product-limit method of Kaplan and Meier.	Up to 1 year

Collaborators and Investigators

• Sponsor: City of Hope Medical Center
• Collaborators: National Cancer Institute (NCI)

Study record dates

Study Major Dates

• Study Start (Actual): October 20, 2020
• Primary Completion (Actual): October 20, 2020
• Study Completion (Actual): October 20, 2020

Study Registration Dates

• First Submitted: October 24, 2018
• First Submitted That Met QC Criteria: November 9, 2018
• First Posted (Actual): November 14, 2018

Study Record Updates

• Last Update Posted (Actual): December 17, 2020
• Last Update Submitted That Met QC Criteria: December 15, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Skin Diseases; Immune System Diseases; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Neoplasms by Site; Disease Attributes; Bone Marrow Diseases; Hematologic Diseases; Myeloproliferative Disorders; Hypersensitivity; Neoplasms, Connective Tissue; Immune Complex Diseases; Neoplasms; Lymphoma; Hematologic Neoplasms; Leukemia; Leukemia, Myeloid; Hodgkin Disease; Recurrence; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Mastocytosis, Systemic; Leukemia, Hairy Cell; Leukemia, Biphenotypic, Acute; Physiological Effects of Drugs; Immunologic Factors; Antibodies; Immunoglobulins; Antibodies, Monoclonal; Antibodies, Bispecific
• Other Study ID Numbers: 18368 (Other Identifier: City of Hope Medical Center); NCI-2018-02320 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No